Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome
- 39 Downloads
Objectives: To conduct a cost-minimisation analysis of sivelestat sodium hydrate treatment for patients in the intensive care unit (ICU) with acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS) caused by infection.
Design: The analysis was performed based on data from a phase III randomised, multicentre, double-blind, controlled clinical study of up to 14 days treatment with sivelestat, in which the effect of intravenous sivelestat at a high dose (0.20 mg/kg/h; the sivelestat group) was compared with that at a low dose (0.004 mg/kg/h, effectively a placebo; the control group).
Patients: Patients with ALI associated with SIRS caused by infection, who began their treatment under mechanical ventilation management in the ICU.
Methods: A four-stage Markov model was constructed to represent the possible conditions of an ALI patient: ICU plus intubated mechanical ventilation; ICU plus weaned from a mechanical ventilator; admission to the general ward; and death. The base-case analysis used a mechanical ventilator weaning daily rate of 2.9% for the control group and 4.0% for the sivelestat group, and the same mortality (1.2%) for both groups at all stages of the Markov model. Medical costs were estimated from standard fees and Japanese National Health Insurance drug prices included fees for hospitalisation within the ICU and general wards, mechanical ventilation, examinations and drug expenditure. Costs were in 2001 values. Sensitivity analyses were performed by varying the weaning rate, mortality, time between weaning and discharge to the general ward, and drug costs.
Perspective: Payers of healthcare costs.
Main Outcomes: The expected 30-day medical costs per patient in the control and sivelestat groups were Japanese yen (¥) 4 144 887 and ¥3 975 451, respectively; a difference of ¥169 436. Drug expenditure accounted for more than half of the medical costs for each group. The periods under mechanical ventilation management and in the ICU for the sivelestat group were shorter than those for the control group by 2 and 1.8 days, respectively. This was of significance in the reduction of the medical costs. A sensitivity analysis suggested that the expected costs for the sivelestat group exceeded those for the control group when the daily weaning rate for the sivelestat group was <3.5%, and also when mortality rates were set at 0.9% in the sivelestat group and 1.4% in the control group.
Conclusions: This analysis suggests that from the Japanese healthcare payer perspective, treatment with sivelestat may reduce medical costs compared with standard care for patients with ALI associated with SIRS caused by infection.
KeywordsIntensive Care Unit Medical Cost Acute Lung Injury Systemic Inflammatory Response Syndrome General Ward
Dr Aikawa was a principal investigator for the clinical study and a supervising editor for the design of the analysis and preparation of the article manuscript. Dr Fujishima was a co-investigator for the clinical study and also contributed to the design of the analysis. Mr Kobayashi constructed the model for analysis. Mr Abiru supported the interpretation of the data of the analysis. Dr Matsuoka was a representative of the sponsor for the clinical study.
Makoto Kobayashi is an employee of CRECON Research & Consulting Inc., Japan. Shozo Matsuoka and Taira Abiru are employees of Ono Pharmaceutical Co. Ltd. The authors have no other conflicts of interests.
This study was supported by Ono Pharmaceutical Co. Ltd, Osaka, Japan.
- 1.Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992 Jun; 101 (6): 1644–55Google Scholar
- 3.Bernard GR, Artigas A, Brigham KL, et al. The AmericanEuropean Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994 Mar; 149 (3 Pt 1): 818–24Google Scholar
- 5.Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Fur J Pharmacol 2002; 451: 1–10Google Scholar
- 6.Tamakuma S, Shiba T, Hirasawa H, et al. A phase III clinical study of a neutrophil elastase inhibitor; ONO-5046•Na in SIRS patients [in Japanese]. Rinshoiyaku 1998 Feb; 14 (2): 289–318Google Scholar
- 7.Fujishima S, Aikawa N, Kobayashi M, et al. Cost analysis of ONO-5046•Na for acute lung injury associated with systemic inflammatory response syndrome [in Japanese]. Rinsho to Kenkyu 2002 Jul; 79 (7): 1251–8Google Scholar
- 8.Ishizawa Y, Dohi S, Mizutani T, et al. An investigation of patients with hematological disorders who need the ICU management [in Japanese]. Nihon Iji Shinpo 1990; 3479: 47–50Google Scholar